Alopecia Areata Pipeline Expands With Horizon Therapeutics’ Bempikibart

Horizon Therapeutics is a global pharmaceutical company with multiple candidates for alopecia areata in its portfolio. On September 13, 2023, Horizon announced that, in conjunction with its partner Q32 Bio, it had initiated a phase 2 clinical trial for bempikibart in adults with severe alopecia areata. Bempikibart (formerly known as ADX-914) is a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function by blocking signaling mediated by both IL-7 and TSLP. 

In addition, Horizon Therapeutics also has another drug candidate, daxdilimab, currently being trialed for AA at phase 2

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.